KKR commits $60 mln to Slayback Pharma
Slayback Pharma, LLC said Jan. 5 that it closed a $60 million commitment from KKR. Slayback, of Princeton Junction, New Jersey, is a pharmaceutical company focused on the development of complex generic and specialty pharmaceutical products.
5 January 2017•3 mins read
